Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, ...
Tag: AC5
Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity
FRAMINGHAM, Mass., Sept. 12, 2017, ARTH, (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel ...
Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
Comments Delivered During Presentation at RHK Capital 2017 Disruptive Growth & Healthcare Conference at 10:45 a.m. ET Today FRAMINGHAM, MA-- ...
© Copyright 2022 publicwire.com